Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Medication Market Size, Share & Trends Analysis Report" report has been added to ResearchAndMarkets.com's offering.
The global anti-obesity medication market size is expected to reach USD 77.24 billion by 2030 and is expected to grow at a CAGR of 31.66% from 2024 to 2030
The market is experiencing significant growth driven by the increasing prevalence of obesity, leading to increased demand for effective treatments. The market's expansion is supported by technological advancements and initiatives by both market players and governments.
The market players are actively pursuing strategic initiatives to expand their service reach through partnerships, mergers, acquisitions, and collaborations. These initiatives are aimed at driving market share growth. For instance, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling over USD 2.32 billion, will boost capacity for chronic disease treatments, potentially including weight management medications.
In addition, governments and healthcare organizations prioritize obesity prevention and treatment, collaborative efforts are shaping regulatory frameworks and fostering innovation. This highlights the market's collective effort. For instance, in June 2023, the UK launched a USD 50.50 million pilot to broaden access to overweight drugs such as Semaglutide (Wegovy) beyond hospital environments, aligning with the government's comprehensive approach to addressing overweight.
Moreover, social media influence and forged prescriptions indicate non-diabetic usage for weight loss, prompting ANSM (Agence nationale de securite du medicament et des produits de sante) to emphasize Ozempic's intended use solely for diabetes treatment. However, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling overUSD 2.32 billion, will boost capacity for chronic disease treatments, potentially including anti-obesity medications. Despite regulatory challenges, such investments indicate optimism for the future of the anti-obesity medication market in France, suggesting a positive trajectory in the projected period.
The rising obesity has a direct impact on the expansion of the obesity treatment industry, providing new business opportunities for pharmaceutical firms, healthcare services, and related parties. With the costs linked to managing obesity increasing, there is a pressing need for creative strategies and measures to combat this health crisis and achieve sustainable cost control within the healthcare sector.
Anti-obesity Medication Market Report Highlights
- By products, the approved segment accounted for the largest market share in 2023. It is expected to grow at a lucrative CAGR over the forecast period, owing to the accessibility of therapeutically effective weight management drugs
- Based on mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share in 2023. The ability of these drugs to enhance the absorption of nutrients and reduce the feeling of hunger is anticipated to bode well for the segment's growth.
- Retail pharmacies dominated the distribution channel segment in 2023, owing to the convenient access to medications for consumers, often located in easily accessible locations within communities
- North America dominated the market for anti-obesity medication in 2023, due to the region's high prevalence of obesity and supportive government policies
- Asia Pacific is anticipated to exhibit the fastest CAGR from 2024 to 2030, due to rising obesity and governmental initiatives across countries like China, Japan, and India. The rising investment in research by pharmaceutical companies is also expected to contribute to this growth.
Company Profiles
- Novo Nordisk A/S
- GSK plc
- Novartis AG
- VIVUS LLC
- Currax Pharmaceuticals LLC
- Boehringer Ingelheim International GmbH
- Rhythm Pharmaceuticals, Inc.
- Gelesis
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Anti-Obesity Medication Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Prevalence of Obesity-Related Conditions
3.2.1.2. Government Regulations and Guidelines
3.2.1.3. Increase in technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Side Effects and Adverse Reactions
3.2.2.2. High cost of anti-obesity drugs
3.3. Anti-Obesity Medication Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. Anti-Obesity Medication Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Anti-Obesity Medication Market by Product Outlook
4.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Approved
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Bupropion-naltrexone (Contrave)
4.4.1.2. Liraglutide (Saxenda)
4.4.1.3. Orlistat
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3.2. Xenical
4.4.1.3.3. Alli
4.4.1.4. Phentermine-topiramate (Qsymia)
4.4.1.5. Semaglutide (Wegovy)
4.4.1.6. Setmelanotide (Imcivree)
4.4.1.7. Tirzepatide (Zepbound)
4.4.2. Off Label
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.1. Semaglutide (Ozempic)
4.4.2.1.2. Liraglutide (Victoza)
4.4.2.1.3. Dulaglutide (Trulicity)
4.4.2.1.4. Topiramate (Dulaglutide (Trulicity))
Chapter 5. Anti-Obesity Medication Market: Mechanism of Action Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Anti-Obesity Medication Market Movement Analysis
5.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
5.4. Peripherally Acting Drugs
5.5. Centrally Acting Drugs
Chapter 6. Anti-Obesity Medication Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Anti-Obesity Medication Market Movement Analysis
6.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Retail Pharmacies
6.5. Hospital Pharmacies
Chapter 7. Anti-Obesity Medication Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
For more information about this report visit https://www.researchandmarkets.com/r/yyu6hy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
